---
title: "Weekly Recap | PPH.US +0.46%, sector split on mixed news"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302943179.md"
description: "PPH.US rose 0.46% this week to close at $114.93, outperforming the S&P 500 by roughly 0.93 percentage points. The fund moved higher before pulling back: it opened Monday at $113.81, climbed to a weekly high of $118.03 on Thursday (22 Oct), then gave back gains to finish at $114.93 on Friday. Weekly amplitude came to 4.06%, with average daily volume of around 463,000 shares, well above the prior median level."
datetime: "2026-10-24T04:43:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302943179.md)
  - [en](https://longbridge.com/en/news/302943179.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302943179.md)
generator: "portal-rs"
---

# Weekly Recap | PPH.US +0.46%, sector split on mixed news

## The Week

PPH.US rose 0.46% this week to close at $114.93, outperforming the S&P 500 by roughly 0.93 percentage points. The fund moved higher before pulling back: it opened Monday at $113.81, climbed to a weekly high of $118.03 on Thursday (22 Oct), then gave back gains to finish at $114.93 on Friday. Weekly amplitude came to 4.06%, with average daily volume of around 463,000 shares, well above the prior median level.

## Sector News

The pharmaceutical sector saw a heavy news flow this week. Eli Lilly (LLY) broke ground on a $5 billion integrated ADC plant in Virginia and advanced its plan to build 10 new US sites since 2020, while also striking a $1.1 billion AI-enabled drug-delivery deal with Metis TechBio. Merck (MRK) and Moderna (MRNA) reported that their personalised mRNA cancer vaccine cut the risk of melanoma recurrence or death by more than 40% in a Phase 3 study, though an embargo breach sent Moderna shares down about 18% in a single session. Elsewhere, GSK (GSK) won FDA approval for a hepatitis B drug, while Bristol Myers Squibb (BMY) came under pressure after disclosing a patient death in an early-stage autoimmune disease trial.

## The Week Ahead

A busy macro calendar lies ahead. The US releases durable goods orders, FHFA house price data and consumer confidence on Tuesday (27 Oct), with the Dallas Fed manufacturing index due on Monday (26 Oct). These readings may shape expectations around the interest-rate path, with particular relevance for rate-sensitive, dividend-paying pharma names. Investors will also watch for any follow-up on the Merck-Moderna cancer vaccine data leak and further disclosures from Bristol Myers Squibb’s autoimmune study.

## In Short

PPH.US’s modest weekly gain played out against clear divergence within the sector: Lilly’s capacity expansion and the Merck-Moderna vaccine data provided upward momentum, while Bristol Myers’ safety issue and Moderna’s data leak weighed on sentiment. On the latest trading day, turnover rate stood at 2.490%, with medium-lot money turning net seller and small-lot money net buyer, offering no clear directional signal. The key question now is whether the coming macro data offers a firmer rate narrative and whether the individual company events broaden into a sector-wide move.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [PPH.US](https://longbridge.com/en/quote/PPH.US.md)

## Related News & Research

- [CoreWeave AI Growth Comes With More Than $35 Billion in Debt](https://longbridge.com/en/news/303108283.md)
- [Verizon CEO Says SpaceX May Be Years Away From Becoming America's 'Sixth' Wireless Competitor](https://longbridge.com/en/news/303109070.md)
- [Micron Suffers a 99.8% Snub From Its Union, Exposing AI's Human Fault Line](https://longbridge.com/en/news/303110941.md)
- [Moderna, Inc. $MRNA Shares Sold by IFP Advisors Inc](https://longbridge.com/en/news/303041682.md)
- [AppLovin Corporation $APP Stock Purchased by Hedeker Wealth LLC](https://longbridge.com/en/news/303049441.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**